Monte Rosa Therapeutics
(NASDAQ) GLUE
Monte Rosa Therapeutics Financials at a Glance
Market Cap
$1.37B
Revenue (TTM)
$123.67M
Net Income (TTM)
$38.63M
EPS (TTM)
$-0.62
P/E Ratio
-27.70
Dividend
$0.00
Beta (Volatility)
0.00 (Low)
Dividend
$0.00
Beta (Volatility)
0.00 (Low)
Price
$17.08
Volume
30,441
Open
$16.80
Price
$17.08
Volume
30,441
Open
$16.80
Previous Close
$17.08
Daily Range
$16.78 - $17.84
52-Week Range
$3.50 - $25.77
Dividend
$0.00
Beta (Volatility)
0.00 (Low)
Price
$17.08
Volume
30,441
Open
$16.80
Previous Close
$17.08
Daily Range
$16.78 - $17.84
52-Week Range
$3.50 - $25.77
GLUE News
GLUE: Motley Fool Moneyball Superscore
Our CEO Is Handing Members His Secret Weapon
It's called Motley Fool Moneyball, our new proprietary AI tool
We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.
Get Access NowAbout Monte Rosa Therapeutics
Industry
Biotechnology
Sector
Health CareEmployees
150
CEO
Markus Warmuth, MD
Website
www.monterosatx.comHeadquarters
Boston, MA 02210, US
GLUE Financials
Key Financial Metrics (TTM)
Gross Margin
97%
Operating Margin
-44%
Net Income Margin
-31%
Return on Equity
-17%
Return on Capital
-14%
Return on Assets
-9%
Earnings Yield
-3.61%
Dividend Yield
0.00%
Payout Ratio
0.00%
Stock Overview
Market Cap
$1.37B
Shares Outstanding
80.02M
Volume
30.44K
Short Interest
0.00%
Avg. Volume
1.68M
Financials (TTM)
Gross Profit
$115.32M
Operating Income
$54.21M
EBITDA
$45.85M
Operating Cash Flow
$22.80M
Capital Expenditure
$4.70M
Free Cash Flow
$27.50M
Cash & ST Invst.
$377.10M
Total Debt
$39.19M
Monte Rosa Therapeutics Performance Analysis
Revenue Growth Rate
Annual and quarterly growth comparisonEarnings Per Share Growth Rate
Annual and quarterly EPS growth comparisonQuarterly Performance
Revenue
$2.78M
-95.4%
Gross Profit
$693.00K
-98.9%
Gross Margin
24.92%
N/A
Market Cap
$1.37B
N/A
Market Cap/Employee
$9.63M
N/A
Employees
142
N/A
Net Income
$46.13M
-443.3%
EBITDA
$47.63M
-416.1%
Quarterly Fundamentals
Net Cash
$337.91M
+2.6%
Accounts Receivable
$4.60M
+2559.0%
Inventory
$0.00
N/A
Long Term Debt
$34.79M
-10.8%
Short Term Debt
$4.40M
+18.4%
Return on Assets
-8.61%
N/A
Return on Invested Capital
-14.10%
N/A
Free Cash Flow
$43.78M
-134.0%
Operating Cash Flow
$43.01M
-133.4%